American Association for Cancer Research
Browse (33.05 kB)

Supplemental Figure S4 from HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth

Download (33.05 kB)
posted on 2023-04-03, 17:10 authored by Terry R. Medler, Justin M. Craig, Alyson A. Fiorillo, Yvonne B. Feeney, J. Chuck Harrell, Charles V. Clevenger

S4. Bufexamac inhibits MDA-MB-231 tumor growth in vivo.



Avon, and Lynn Sage Foundations


American Cancer Society

Medical Research Foundation

Cathy and Jim Rudd Career Development




Stat5a is a transcription factor utilized by several cytokine/hormone receptor signaling pathways that promotes transcription of genes associated with proliferation, differentiation, and survival of cancer cells. However, there are currently no clinically approved therapies that directly target Stat5a, despite ample evidence that it contributes to breast cancer pathogenesis. Here, deacetylation of the Stat5a coactivator and chromatin-remodeling protein HMGN2 on lysine residue K2 by HDAC6 promotes Stat5a-mediated transcription and breast cancer growth. HDAC6 inhibition both in vitro and in vivo enhances HMGN2 acetylation with a concomitant reduction in Stat5a-mediated signaling, resulting in an inhibition of breast cancer growth. Furthermore, HMGN2 is highly acetylated at K2 in normal human breast tissue, but is deacetylated in primary breast tumors and lymph node metastases, suggesting that targeting HMGN2 deacetylation is a viable treatment for breast cancer. Together, these results reveal a novel mechanism by which HDAC6 activity promotes the transcription of Stat5a target genes and demonstrate utility of HDAC6 inhibition for breast cancer therapy.Implications: HMGN2 deacetylation enhances Stat5a transcriptional activity, thereby regulating prolactin-induced gene transcription and breast cancer growth. Mol Cancer Res; 14(10); 994–1008. ©2016 AACR.